<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Orthop Surg Res</journal-id><journal-id journal-id-type="iso-abbrev">J Orthop Surg Res</journal-id><journal-id journal-id-type="pmc-domain-id">438</journal-id><journal-id journal-id-type="pmc-domain">jorthsurg</journal-id><journal-title-group><journal-title>Journal of Orthopaedic Surgery and Research</journal-title></journal-title-group><issn pub-type="epub">1749-799X</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC5839069</article-id><article-id pub-id-type="pmcid-ver">PMC5839069.1</article-id><article-id pub-id-type="pmcaid">5839069</article-id><article-id pub-id-type="pmcaiid">5839069</article-id><article-id pub-id-type="pmid">29506541</article-id><article-id pub-id-type="doi">10.1186/s13018-018-0747-8</article-id><article-id pub-id-type="publisher-id">747</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Efficacy of naproxen prophylaxis for the prevention of heterotopic ossification after hip surgery: a meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Ma</surname><given-names initials="R">Ran</given-names></name><address><email>drmaran008@qq.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Chen</surname><given-names initials="GH">Guan-Hong</given-names></name><address><email>chenguanghongtou0@qq.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="LJ">Liu-Jing</given-names></name><address><email>zhaoliujingdr0@qq.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhai</surname><given-names initials="XC">Xi-Cheng</given-names></name><address><email>zhaixicheng08@126.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Department of Orthopedics, Shanxian Central Hospital, No.1 Wenhua Road, Shanxian, Shandong 274300 China </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>13</volume><issue-id pub-id-type="pmc-issue-id">304048</issue-id><elocation-id>48</elocation-id><history><date date-type="received"><day>11</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>19</day><month>2</month><year>2018</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>03</month><year>2018</year></date></event><event event-type="pmc-live"><date><day>09</day><month>03</month><year>2018</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2018-03-28 03:13:41.413"><day>28</day><month>03</month><year>2018</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13018_2018_Article_747.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">This meta-analysis aimed to assess whether the specific nonsteroidal anti-inflammatory drug (NSAID) naproxen has a role in reducing the occurrence of heterotopic ossification after hip surgery.</p></sec><sec><title>Methods</title><p id="Par2">Potential studies were identified in the following electronic databases: PubMed, EMBASE, Web of Science, Cochrane Library, and Google. We included studies involving hip surgery patients in which the intervention group received naproxen and the control group received placebo. The occurrence of heterotopic ossification and complications were the final outcomes. Stata 13.0 was used for the meta-analysis.</p></sec><sec><title>Results</title><p id="Par3">Four randomized controlled trials (RCTs) involving 269 patients were ultimately included in this meta-analysis. The use of naproxen was associated with a significant reduction in the occurrence of heterotopic ossification at 1.5-, 3-, 6-, and 12-month follow-ups (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). There was no significant difference in the occurrence of complications between treatment and control groups (<italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05).</p></sec><sec><title>Conclusion</title><p id="Par4">Our analysis indicates that naproxen can decrease the occurrence of heterotopic ossification without increasing complications in hip surgery patients. Due to the limited number of studies included, more high-quality RCTs are needed to identify the optimal dose of naproxen.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Naproxen</kwd><kwd>Hip surgery</kwd><kwd>Heterotopic ossification</kwd><kwd>Meta-analysis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par13">Heterotopic ossification (HO) was one of the most common complications of hip surgery. Indeed, HO, which is mainly induced by an inflammatory response to surgery, undermines the intended benefits of surgery [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Due to variability in hip surgical techniques, the incidence of HO after such a procedure varies from 0 to 73% [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Histologically, HO consists of lamellar bone derived from abnormity activity of osteoblast cells in atypical locations [<xref ref-type="bibr" rid="CR5">5</xref>]. HO decreases range of motion (ROM) and causes hip pain, swelling, and joint stiffness.</p><p id="Par14">Nonsteroidal anti-inflammatory drugs (NSAIDs) and radiotherapy are often used to reduce the occurrence of HO after hip surgery [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Although NSAIDs have been widely used for HO prophylaxis, the risk of gastrointestinal side effects has drawn the attention of surgeons. Thus, radiotherapy may be a preferred option in very high-risk patients or in those with contraindications to NSAIDs. Nonetheless, NSAIDs are considerably more cost effective than radiotherapy.</p><p id="Par15">Different drugs have been used for HO prophylaxis, though NSAIDs have been the mainstay [<xref ref-type="bibr" rid="CR7">7</xref>], with greatly variable efficacy. The efficacy of naproxen, a type of NSAID, for the prophylaxis of HO after hip surgery remains in debate, and there is yet no relevant meta-analysis on the use of naproxen in this application.</p><p id="Par16">The objective of this meta-analysis was to evaluate the efficacy of naproxen for prophylaxis of HO after hip surgery.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Literature search</title><p id="Par17">Both published and unpublished literature was identified in the following databases: PubMed (1950&#8211;November 2017), EMBASE (1974&#8211;November 2017), Cochrane Library (November 2017 Issue 3), and Google Scholar (1950&#8211;November 2017). The MeSH terms and combinations of terms used in the search were as follows: &#8220;THA&#8221; OR &#8220;THR&#8221; OR &#8220;total hip arthroplasty&#8221; OR &#8220;total hip replacement&#8221; OR &#8220;Arthroplasty, Replacement, Hip&#8221;[Mesh] OR &#8220;hip arthroscopy&#8221; AND &#8220;naproxen&#8221; [Mesh terms] OR &#8220;Naproxen&#8221;[Mesh]. Reference lists of included studies were scrutinized for other relevant publications. Only articles originally written in English or translated into English were considered. When multiple reports describing the same sample were published, the most recent or complete report was utilized. As this meta-analysis collected data from published articles, no ethics approval was necessary for the research.</p></sec><sec id="Sec4"><title>Inclusion and exclusion criteria</title><p id="Par18">Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed for the inclusion of studies in this systematic review and associated meta-analysis [<xref ref-type="bibr" rid="CR8">8</xref>]. The studies had to meet the following standards to qualify: (1) a randomized controlled trial (RCT) design; (2) intervention using naproxen for prophylaxis of HO; (3) a control group receiving either placebo or no intervention; (4) reporting of HO outcomes, including incidence of HO at 1.5, 3, 6, or 12&#160;months after surgery, as well as potential complications. The following exclusion criteria were applied: (1) animal experiments or case reports, (2) failure to provide the final results of interest (incidence of HO at 1.5, 3, 6, or 12&#160;months after surgery, as well as potential complications), and (3) repeated or overlapping publications.</p></sec><sec id="Sec5"><title>Data collection and outcome measures</title><p id="Par19">Two researchers independently extracted the following data from each study that met inclusion criteria: first author, year of publication, country, participant demographic characteristics, and treatment regime for each group. Discrepancies were resolved by consensus. The primary outcome measure for this meta-analysis was the appearance of radiographically determined HO during follow-up. Secondary measures were side effects related to the study medication.</p></sec><sec id="Sec6"><title>Quality assessment</title><p id="Par20">The methodological quality of the included trials was assessed by Cochrane Collaboration&#8217;s tool [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. The following items were assessed: random sequence generation, allocation concealment, blinding of participants, personnel and outcome assessment, incomplete outcome measures, selective outcome reporting, and other bias. Two independent practitioners independently screened and reviewed every entry for accuracy and consistency, and any discrepancies were resolved by consensus.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par21">Stata software, version 13.0 (Stata Corp., College Station, TX), was used to perform the meta-analysis. For dichotomous variables, risk ratios (RRs) with the corresponding 95% confidence intervals (CIs) were calculated; weighted mean differences (WMDs) were used for numerical variables. Where significant heterogeneity was found, data were pooled using a random-effect model. Statistical heterogeneity among individual studies was evaluated based on Cochrane&#8217;s <italic toggle="yes">Q</italic> test and the <italic toggle="yes">I</italic><sup>2</sup> index, and statistical heterogeneity was confirmed if <italic toggle="yes">I</italic><sup>2</sup> was above 75% and <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.10 [<xref ref-type="bibr" rid="CR11">11</xref>]. Publication bias was evaluated using the Egger regression asymmetry test [<xref ref-type="bibr" rid="CR12">12</xref>]. Results were considered statistically significant when the <italic toggle="yes">P</italic> value was less than 0.05.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Trial characteristics</title><p id="Par22">We retrieved 64 relevant reports from electronic databases; of these, we identified 13 eligible studies for further assessment. Four RCTs [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref>] involving 269 patients finally met the predetermined inclusion criteria, as illustrated in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>. All studies reported statistically significant differences in the incidence of HO between patients treated with naproxen and control subjects. Patient demographic details were balanced between medication and control groups in the four included studies. The sample size among trials ranged from 50 to 108. The method of administration of medication varied in dosage and course among the trials. Detailed characteristics of the relevant literature are presented in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>PRISMA flowchart for the included studies</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="13018_2018_747_Fig1_HTML.jpg"/></fig><table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>The general characteristic of the included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Author</th><th colspan="1" rowspan="1">Country</th><th colspan="1" rowspan="1">Sample (I/C)</th><th colspan="1" rowspan="1">Age (I/C)</th><th colspan="1" rowspan="1">Surgery</th><th colspan="1" rowspan="1">Intervention</th><th colspan="1" rowspan="1">Control</th><th colspan="1" rowspan="1">Outcomes</th><th colspan="1" rowspan="1">Follow-up (weeks)</th><th colspan="1" rowspan="1">Study</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Beckmann 2015</td><td colspan="1" rowspan="1">USA</td><td colspan="1" rowspan="1">54/54</td><td colspan="1" rowspan="1">35.1/35.1</td><td colspan="1" rowspan="1">Hip arthroscopy</td><td colspan="1" rowspan="1">Naproxen (500&#160;mg, twice daily, total 3&#160;weeks</td><td colspan="1" rowspan="1">Placebo</td><td colspan="1" rowspan="1">1,2,3,4,5</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">RCTs</td></tr><tr><td colspan="1" rowspan="1">Vielpeau 1999</td><td colspan="1" rowspan="1">France</td><td colspan="1" rowspan="1">28/28</td><td colspan="1" rowspan="1">66/62.8</td><td colspan="1" rowspan="1">THA</td><td colspan="1" rowspan="1">Naproxen (250&#160;mg, 3 times daily, total 6&#160;weeks)</td><td colspan="1" rowspan="1">Placebo</td><td colspan="1" rowspan="1">1,2,3,5</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">RCTs</td></tr><tr><td colspan="1" rowspan="1">Gebuhr 1991</td><td colspan="1" rowspan="1">Denmark</td><td colspan="1" rowspan="1">28/27</td><td colspan="1" rowspan="1">75/70</td><td colspan="1" rowspan="1">THA</td><td colspan="1" rowspan="1">Naproxen (500&#160;mg twice on operation day, 250&#160;mg, 3 times daily, total 4&#160;weeks)</td><td colspan="1" rowspan="1">Placebo</td><td colspan="1" rowspan="1">2,3,5</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">RCTs</td></tr><tr><td colspan="1" rowspan="1">Gebuhr 1995</td><td colspan="1" rowspan="1">Denmark</td><td colspan="1" rowspan="1">27/23</td><td colspan="1" rowspan="1">72/73</td><td colspan="1" rowspan="1">THA</td><td colspan="1" rowspan="1">Naproxen (500&#160;mg twice daily for 7&#160;days from operation day on)</td><td colspan="1" rowspan="1">Placebo</td><td colspan="1" rowspan="1">1,2,3,4</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">RCTs</td></tr></tbody></table><table-wrap-foot><p>1: the occurrence of HO at 1.5&#160;months after surgery; 2: the occurrence of HO at 3&#160;months after surgery; 3: the occurrence of HO at 6&#160;months after surgery; 4: the occurrence of HO at 12&#160;months after surgery; 5: the occurrence of complications</p><p><italic toggle="yes">I</italic> intervention group, <italic toggle="yes">C</italic> control group, <italic toggle="yes">THA</italic> total hip arthroplasty</p></table-wrap-foot></table-wrap></p><p id="Par23">The methodological quality of the included trials is summarized in Figs.&#160;<xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig3" ref-type="fig">3</xref>. All included studies were described as RCTs. Only one study reported acceptable methods of randomization and clearly described the method of allocation concealment [<xref ref-type="bibr" rid="CR13">13</xref>]. Three studies [<xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref>] reported blinding of participants and personnel, whereas one of the trials conducted by Gebuhr [<xref ref-type="bibr" rid="CR16">16</xref>] provided no details in this regard. Selective outcome reporting bias was present, as enrollment of participants was consecutive or male gender was a criterion. Intent-to-treat comparisons were employed in two studies [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref>]. Other biases that existed in the studies included non-uniform surgical projects.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Risk of bias summary for the included studies</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="13018_2018_747_Fig2_HTML.jpg"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Risk of bias graph for the included studies</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="13018_2018_747_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec10"><title>Incidence of HO at 1.5&#160;months after surgery</title><p id="Par24">The incidence of HO at 1.5&#160;months after surgery was reported in three studies [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref>]. No heterogeneity between the included studies was found (<italic toggle="yes">I</italic><sup>2</sup>&#160;=&#8201;0.0%, <italic toggle="yes">P</italic>&#8201;=&#8201;0.761). The pooled results indicated that use of naproxen was associated with reduced occurrence of HO at 1.5&#160;months after surgery (RR&#8201;=&#8201;0.247, 95% CI 0.13, 0.44, <italic toggle="yes">P</italic>&#8201;=&#8201;0.000, Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Forest plot comparing the occurrence of HO at 1.5&#160;months after surgery between the two groups</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="13018_2018_747_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec11"><title>Incidence of HO at 3&#160;months after surgery</title><p id="Par25">Three studies reported the incidence of HO at 3&#160;months after surgery [<xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref>]. Again, no heterogeneity was found (<italic toggle="yes">I</italic><sup>2</sup>&#160;=&#8201;4.0%, <italic toggle="yes">P</italic>&#8201;=&#8201;0.353). The pooled results indicated naproxen administration to be associated with reduced HO occurrence at 3&#160;months after surgery (RR&#8201;=&#8201;0.35, 95% CI 0.21, 0.58, <italic toggle="yes">P</italic>&#8201;=&#8201;0.000, Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Forest plot comparing the occurrence of HO at 3&#160;months after surgery between the two groups</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO5" position="float" orientation="portrait" xlink:href="13018_2018_747_Fig5_HTML.jpg"/></fig></p></sec><sec id="Sec12"><title>Incidence of HO at 6&#160;months after surgery</title><p id="Par26">Similarly, the incidence of HO at 6&#160;months after surgery was reported in three studies [<xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref>], and no heterogeneity between the included studies was observed (<italic toggle="yes">I</italic><sup>2</sup>&#160;=&#8201;0.0%, <italic toggle="yes">P</italic>&#8201;=&#8201;0.489). Based on the pooled results, administration of naproxen was associated with a reduction in the occurrence of HO at 6&#160;months post-surgery (RR&#8201;=&#8201;0.38, 95% CI 0.24, 0.60, <italic toggle="yes">P</italic>&#8201;=&#8201;0.020, Fig.&#160;<xref rid="Fig6" ref-type="fig">6</xref>).<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Forest plot comparing the occurrence of HO at 6&#160;months after surgery between the two groups</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO6" position="float" orientation="portrait" xlink:href="13018_2018_747_Fig6_HTML.jpg"/></fig></p></sec><sec id="Sec13"><title>Incidence of HO at 12&#160;months after surgery</title><p id="Par27">All four studies reported the incidence of HO at 12&#160;months after surgery [<xref ref-type="bibr" rid="CR13">13</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref>]. There was no heterogeneity between the included studies (<italic toggle="yes">I</italic><sup>2</sup>&#160;=&#8201;0.0%, <italic toggle="yes">P</italic>&#8201;=&#8201;0.578). According to the pooled results, naproxen administration was associated with decreases in the occurrence of HO at 12&#160;months after surgery (RR&#8201;=&#8201;0.21, 95% CI 0.11, 0.76, <italic toggle="yes">P</italic>&#8201;=&#8201;0.000, Fig.&#160;<xref rid="Fig7" ref-type="fig">7</xref>).<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Forest plot comparing the occurrence of HO at 12&#160;months after surgery between the two groups</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO7" position="float" orientation="portrait" xlink:href="13018_2018_747_Fig7_HTML.jpg"/></fig></p></sec><sec id="Sec14"><title>Complications</title><p id="Par28">The incidence of complications after surgery was reported in two studies [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], with no heterogeneity observed between the studies (<italic toggle="yes">I</italic><sup>2</sup>&#160;=&#8201;0.0%, <italic toggle="yes">P</italic>&#8201;=&#8201;0.719). The pooled results indicated that use of naproxen had no impact on complications after hip surgery (RR&#8201;=&#8201;1.26, 95% CI 0.83, 1.93, <italic toggle="yes">P</italic>&#8201;=&#8201;0.282, Fig.&#160;<xref rid="Fig8" ref-type="fig">8</xref>).<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p>Forest plot comparing the occurrence of complications after surgery between the two groups</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO8" position="float" orientation="portrait" xlink:href="13018_2018_747_Fig8_HTML.jpg"/></fig></p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par29">This is the first meta-analysis that compares naproxen versus placebo for reducing the occurrence of HO after hip surgery. Based on the results of our meta-analysis, we found naproxen to be effective in reducing the occurrence of HO at 1.5-, 3-, 6-, and 12-month follow-ups. In addition, naproxen use did not increase the incidence of complications after hip surgery. The major strengths of our analysis include our systematic approach in identifying studies from PubMed, EMBASE, Web of Science, Cochrane Library, and Google databases and our rigorous data analysis.</p><p id="Par30">We assessed the incidence of HO at 12&#160;months after hip surgery, and the results showed that naproxen can reduce its occurrence. HO, which has many diverse causes and pathogenies, can be classified into the following three main types: genetic, neurogenic, and traumatic [<xref ref-type="bibr" rid="CR17">17</xref>]. It is well known that higher grades of HO are associated with functional disabilities. Recently, clinically relevant HO has been defined as Brooker grade 3 or 4. The morbidity of definite HO following total hip arthroplasty (THA) ranges from 3 to 9%. We did not compare functional outcomes after surgery between the two groups because there was insufficient data for such an analysis.</p><p id="Par31">In this meta-analysis, the two studies conducted by Gebuhr et al. taken together indicate that naproxen provided for either 4&#160;weeks or 8&#160;days is equally sufficient to decrease the incidence of HO [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>] Further studies are required to investigate shorter courses of treatment regimens following hip surgery. Although there is increasing evidence for the use of selective COX-2 inhibitors, which have been shown to produce fewer gastrointestinal side effects than NSAIDs, there are concerns due to the emergence of evidence of adverse cardiovascular complications, particularly in patients with cardiovascular disease or risk factors. For example, rofecoxib, a COX-2-inhibiting agent, has been withdrawn from the market. The Vioxx Gastrointestinal Outcomes Research (VIGOR) trial conducted by Bombardier indicated that rofecoxib can lower the incidence of clinically significant grades of HO, with lower rates of gastrointestinal toxicity but with higher incidence of myocardial infarction compared to naproxen [<xref ref-type="bibr" rid="CR18">18</xref>]. Simultaneous prescription of mucoprotective agents with NSAIDs reduces gastrointestinal irritation, though this line of treatment should be reserved for patients who must avoid traditional NSAIDs (i.e., indomethacin and naproxen) due to a severe gastrointestinal disorder and for those who do not have significant cardiac risk factors.</p><p id="Par32">In general, HO was assessed either via clinical outcomes using the Harris hip score and ROM or radiological outcomes using plain radiographs or Brooker classification [<xref ref-type="bibr" rid="CR19">19</xref>]. By measuring the volume of heterotopic bone formation, other methods such as the 3-D computed tomography reconstructions used in Matta et al. may be more convincing for rating HO [<xref ref-type="bibr" rid="CR20">20</xref>]. HO can typically be first diagnosed 6 to 12&#160;weeks post-trauma [<xref ref-type="bibr" rid="CR21">21</xref>]. It has also been reported that HO can be detected by ultrasound as early as 1&#160;week following surgery [<xref ref-type="bibr" rid="CR22">22</xref>]; thus, ultrasound may play a strong role not only in the early diagnosis of HO but also in adapting or commencing prophylactic therapy.</p><p id="Par33">Serious complications of NSAID prophylaxis have been reported following hip surgery, including ototoxicity, renal failure, and hematochezia. However, there was no significant difference in the occurrence of complications between the naproxen and control groups (<italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05). Beckmann et al. [<xref ref-type="bibr" rid="CR13">13</xref>] reported minor adverse reactions in 42% of patients taking naproxen and 35% of those taking placebo. Moreover, Vielpeau et al. [<xref ref-type="bibr" rid="CR14">14</xref>] found that overall tolerance was rated as good by 87% of patients and 86% of physicians, with no difference between groups.</p><p id="Par34">According to the evidence available, successful prophylaxis following hip surgery can be achieved using a course of naproxen ranging from 8&#160;days to 6&#160;weeks at a dose of 500&#160;mg twice daily or 250&#160;mg three times daily. Further studies are needed to evaluate whether naproxen has an advantage over other NSAIDs in the prevention of clinically significant HO.</p><p id="Par35">Only four RCTs were included in this meta-analysis. Despite the great risk for publication bias, other published and unpublished data, administration of interventions, timing of applying naproxen, or methods of outcome assessment might result in significant differences. To guide its clinical application, more studies are needed to verify whether naproxen is more efficient than other NSAIDs for preventing clinical HO. Further efforts are needed to improve the clinical application of HO prophylaxis, for naproxen or other NSAIDs.</p></sec><sec id="Sec16"><title>Conclusions</title><p id="Par36">In light of the positive effect of naproxen in reducing the occurrence of HO with no observed adverse impact on safety outcomes, naproxen may be used as an alternative to prevent HO after hip surgery. Further research is necessary to assess the impact of naproxen on decreasing the incidence of HO compared to other NSAIDs as well as to determine the optimal dose and treatment interval.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CI</term><def><p id="Par5">Confidence interval</p></def></def-item><def-item><term>HO</term><def><p id="Par6">Heterotopic ossification</p></def></def-item><def-item><term>NSAIDs</term><def><p id="Par7">Nonsteroidal anti-inflammatory drugs</p></def></def-item><def-item><term>RCTs</term><def><p id="Par8">Randomized controlled trials</p></def></def-item><def-item><term>ROM</term><def><p id="Par9">Range of motion</p></def></def-item><def-item><term>RR</term><def><p id="Par10">Risk ratio</p></def></def-item><def-item><term>VIGOR</term><def><p id="Par11">Vioxx Gastrointestinal Outcomes Research</p></def></def-item><def-item><term>WMD</term><def><p id="Par12">Weighted mean difference</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>None</p><sec id="FPar2"><title>Funding</title><p id="Par38">There is no funding for this article.</p></sec><sec id="FPar3"><title>Availability of data and materials</title><p id="Par39">All raw data are presented in the figures included in the article.</p></sec></ack><notes notes-type="COI-statement"><sec id="FPar1"><title>Author contributions</title><p id="Par37">RM and GHC conceived the study design. LJZ and XCZ performed the study, collected the data, and contributed to the study design. LJZ and XCZ prepared the manuscript. RM, GHC, and XCZ edited the manuscript. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Ethics approval and consent to participate</title><p id="Par40">None</p></sec><sec id="FPar5"><title>Consent for publication</title><p id="Par41">Not applicable</p></sec><sec id="FPar6"><title>Competing interests</title><p id="Par42">The authors declare that they have no competing interests.</p></sec><sec id="FPar7"><title>Publisher&#8217;s Note</title><p id="Par43">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>PB</given-names></name><name name-style="western"><surname>Ramkumar</surname><given-names>PN</given-names></name><name name-style="western"><surname>Meftah</surname><given-names>M</given-names></name><etal/></person-group><article-title>Incidence of heterotopic ossification following a multimodal pain protocol in total hip arthroplasty with the posterior approach</article-title><source>Orthopedics</source><year>2017</year><volume>41</volume><issue>1</issue><fpage>e92</fpage><lpage>e97</lpage><pub-id pub-id-type="doi">10.3928/01477447-20171102-01</pub-id><pub-id pub-id-type="pmid">29120007</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>PC</given-names></name><name name-style="western"><surname>Camou</surname><given-names>E</given-names></name><name name-style="western"><surname>Wofford</surname><given-names>K</given-names></name></person-group><article-title>The impact of cigarette smoking on the formation of heterotopic ossification among service members with a traumatic amputation</article-title><source>Mil Med</source><year>2017</year><volume>182</volume><issue>5</issue><fpage>e1742</fpage><lpage>e1748</lpage><pub-id pub-id-type="doi">10.7205/MILMED-D-16-00350</pub-id><pub-id pub-id-type="pmid">29087919</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qureshi</surname><given-names>AT</given-names></name><name name-style="western"><surname>Dey</surname><given-names>D</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Inhibition of mammalian target of rapamycin signaling with rapamycin prevents trauma-induced heterotopic ossification</article-title><source>Am J Pathol</source><year>2017</year><volume>187</volume><issue>11</issue><fpage>2536</fpage><lpage>2545</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2017.07.010</pub-id><pub-id pub-id-type="pmid">29029772</pub-id><pub-id pub-id-type="pmcid">PMC5809339</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Cholok D, Chung MT, Ranganathan K, et al. Heterotopic ossification and the elucidation of pathologic differentiation. Bone. 2017; [Epub ahead of print].<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bone.2017.09.019</pub-id><pub-id pub-id-type="pmcid">PMC6585944</pub-id><pub-id pub-id-type="pmid">28987285</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mary Jiayi</surname><given-names>T</given-names></name><name name-style="western"><surname>Linda</surname><given-names>P</given-names></name><name name-style="western"><surname>Michael</surname><given-names>P</given-names></name><etal/></person-group><article-title>Potential discrepancy between plain films and CT scans in Brooker classification of heterotopic ossification</article-title><source>Br J Radiol</source><year>2017</year><volume>90</volume><issue>1080</issue><fpage>20170263</fpage><pub-id pub-id-type="doi">10.1259/bjr.20170263</pub-id><pub-id pub-id-type="pmid">28972793</pub-id><pub-id pub-id-type="pmcid">PMC6047644</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milakovic</surname><given-names>M</given-names></name><name name-style="western"><surname>Popovic</surname><given-names>M</given-names></name><name name-style="western"><surname>Raman</surname><given-names>S</given-names></name><etal/></person-group><article-title>Radiotherapy for the prophylaxis of heterotopic ossification: a systematic review and meta-analysis of randomized controlled trials</article-title><source>Radiother Oncol</source><year>2015</year><volume>116</volume><issue>1</issue><fpage>4</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2015.05.022</pub-id><pub-id pub-id-type="pmid">26163090</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kan</surname><given-names>SL</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B</given-names></name><name name-style="western"><surname>Ning</surname><given-names>GZ</given-names></name><etal/></person-group><article-title>Nonsteroidal anti-inflammatory drugs as prophylaxis for heterotopic ossification after total hip arthroplasty: a systematic review and meta-analysis</article-title><source>Medicine (Baltimore)</source><year>2015</year><volume>94</volume><issue>18</issue><fpage>e828</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000000828</pub-id><pub-id pub-id-type="pmid">25950691</pub-id><pub-id pub-id-type="pmcid">PMC4602535</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liberati</surname><given-names>A</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name><name name-style="western"><surname>Tetzlaff</surname><given-names>J</given-names></name><etal/></person-group><article-title>The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration</article-title><source>BMJ</source><year>2009</year><volume>339</volume><fpage>b2700</fpage><pub-id pub-id-type="doi">10.1136/bmj.b2700</pub-id><pub-id pub-id-type="pmid">19622552</pub-id><pub-id pub-id-type="pmcid">PMC2714672</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panic</surname><given-names>N</given-names></name><name name-style="western"><surname>Leoncini</surname><given-names>E</given-names></name><name name-style="western"><surname>de Belvis</surname><given-names>G</given-names></name><etal/></person-group><article-title>Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>12</issue><fpage>e83138</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0083138</pub-id><pub-id pub-id-type="pmid">24386151</pub-id><pub-id pub-id-type="pmcid">PMC3873291</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slim</surname><given-names>K</given-names></name><name name-style="western"><surname>Nini</surname><given-names>E</given-names></name><name name-style="western"><surname>Forestier</surname><given-names>D</given-names></name><etal/></person-group><article-title>Methodological index for non-randomized studies (minors): development and validation of a new instrument</article-title><source>ANZ J Surg</source><year>2003</year><volume>73</volume><issue>9</issue><fpage>712</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1046/j.1445-2197.2003.02748.x</pub-id><pub-id pub-id-type="pmid">12956787</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pereira</surname><given-names>TV</given-names></name><name name-style="western"><surname>Patsopoulos</surname><given-names>NA</given-names></name><name name-style="western"><surname>Salanti</surname><given-names>G</given-names></name><etal/></person-group><article-title>Critical interpretation of Cochran&#8217;s Q test depends on power and prior assumptions about heterogeneity</article-title><source>Res Synth Methods</source><year>2010</year><volume>1</volume><issue>2</issue><fpage>149</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1002/jrsm.13</pub-id><pub-id pub-id-type="pmid">26061380</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bowden</surname><given-names>J</given-names></name><name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>S</given-names></name></person-group><article-title>Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression</article-title><source>Int J Epidemiol</source><year>2015</year><volume>44</volume><issue>2</issue><fpage>512</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1093/ije/dyv080</pub-id><pub-id pub-id-type="pmid">26050253</pub-id><pub-id pub-id-type="pmcid">PMC4469799</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beckmann</surname><given-names>JT</given-names></name><name name-style="western"><surname>Wylie</surname><given-names>JD</given-names></name><name name-style="western"><surname>Potter</surname><given-names>MQ</given-names></name><etal/></person-group><article-title>Effect of naproxen prophylaxis on heterotopic ossification following hip arthroscopy: a double-blind randomized placebo-controlled trial</article-title><source>J Bone Joint Surg Am</source><year>2015</year><volume>97</volume><issue>24</issue><fpage>2032</fpage><lpage>2037</lpage><pub-id pub-id-type="doi">10.2106/JBJS.N.01156</pub-id><pub-id pub-id-type="pmid">26677237</pub-id><pub-id pub-id-type="pmcid">PMC4673445</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vielpeau</surname><given-names>C</given-names></name><name name-style="western"><surname>Joubert</surname><given-names>JM</given-names></name><name name-style="western"><surname>Hulet</surname><given-names>C</given-names></name></person-group><article-title>Naproxen in the prevention of heterotopic ossification after total hip replacement</article-title><source>Clin Orthop Relat Res</source><year>1999</year><volume>369</volume><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1097/00003086-199912000-00029</pub-id><pub-id pub-id-type="pmid">10611883</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gebuhr</surname><given-names>P</given-names></name><name name-style="western"><surname>Soelberg</surname><given-names>M</given-names></name><name name-style="western"><surname>Orsnes</surname><given-names>T</given-names></name><etal/></person-group><article-title>Naproxen prevention of heterotopic ossification after hip arthroplasty. A prospective control study of 55 patients</article-title><source>Acta Orthop Scand</source><year>1991</year><volume>62</volume><issue>3</issue><fpage>226</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.3109/17453679108993597</pub-id><pub-id pub-id-type="pmid">1904183</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gebuhr</surname><given-names>P</given-names></name><name name-style="western"><surname>Wilbek</surname><given-names>H</given-names></name><name name-style="western"><surname>Soelberg</surname><given-names>M</given-names></name></person-group><article-title>Naproxen for 8 days can prevent heterotopic ossification after hip arthroplasty</article-title><source>Clin Orthop Relat Res</source><year>1995</year><volume>314</volume><issue>314</issue><fpage>166</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">7634631</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balboni</surname><given-names>TA</given-names></name><name name-style="western"><surname>Gobezie</surname><given-names>R</given-names></name><name name-style="western"><surname>Mamon</surname><given-names>HJ</given-names></name></person-group><article-title>Heterotopic ossification: pathophysiology, clinical features, and the role of radiotherapy for prophylaxis</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2006</year><volume>65</volume><issue>5</issue><fpage>1289</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2006.03.053</pub-id><pub-id pub-id-type="pmid">16863921</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bombardier</surname><given-names>C</given-names></name><name name-style="western"><surname>Laine</surname><given-names>L</given-names></name><name name-style="western"><surname>Reicin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><issue>21</issue><fpage>1520</fpage><lpage>1528</lpage><pub-id pub-id-type="doi">10.1056/NEJM200011233432103</pub-id><pub-id pub-id-type="pmid">11087881</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subbarao</surname><given-names>JV</given-names></name><name name-style="western"><surname>Garrison</surname><given-names>SJ</given-names></name></person-group><article-title>Heterotopic ossification: diagnosis and management, current concepts and controversies</article-title><source>J Spinal Cord Med</source><year>1999</year><volume>22</volume><issue>4</issue><fpage>273</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1080/10790268.1999.11719580</pub-id><pub-id pub-id-type="pmid">10751131</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matta</surname><given-names>JM</given-names></name><name name-style="western"><surname>Siebenrock</surname><given-names>KA</given-names></name></person-group><article-title>Does indomethacin reduce heterotopic bone formation after operations for acetabular fractures? A prospective randomised study</article-title><source>J Bone Joint Surg Br</source><year>1997</year><volume>79</volume><issue>6</issue><fpage>959</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1302/0301-620X.79B6.6889</pub-id><pub-id pub-id-type="pmid">9393912</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghalambor</surname><given-names>N</given-names></name><name name-style="western"><surname>Matta</surname><given-names>JM</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>L</given-names></name></person-group><article-title>Heterotopic ossification following operative treatment of acetabular fracture. An analysis of risk factors</article-title><source>Clin Orthop Relat Res</source><year>1994</year><volume>305</volume><fpage>96</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1097/00003086-199408000-00013</pub-id><pub-id pub-id-type="pmid">8050252</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>EA</given-names></name><name name-style="western"><surname>Cassar-Pullicino</surname><given-names>VN</given-names></name><name name-style="western"><surname>McCall</surname><given-names>IW</given-names></name></person-group><article-title>The role of ultrasound in the early diagnosis and management of heterotopic bone formation</article-title><source>Clin Radiol</source><year>1991</year><volume>43</volume><issue>3</issue><fpage>190</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/S0009-9260(05)80478-7</pub-id><pub-id pub-id-type="pmid">1901533</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>